High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?

This publication has 18 references indexed in Scilit:

• Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis
  European Urology, 2018
• Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial
  Journal of Urology, 2018
• Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
  Journal of Clinical Oncology, 2017
• Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy
  World Journal of Urology, 2017
• Adjuvant Treatment for High-Risk Clear Cell Renal Cancer
  JAMA Oncology, 2017
• Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
  New England Journal of Medicine, 2016
• Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
  The Lancet, 2016
• Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research
  Journal of Evaluation in Clinical Practice, 2012
• Conducting Meta-Analyses inRwith themetaforPackage
  Journal of Statistical Software, 2010
• Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
  New England Journal of Medicine, 2007